Probable predictive biomarkers for tumor response to mTOR inhibitors, as have been described in glioblastoma, breast and prostate cancer cells, would be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Hence, this facts is predicated on preclinical assays, according to in vitro cultured tumor mobile strains, which https://jamesx752imq4.snack-blog.com/profile